Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 602526, 16 pages
http://dx.doi.org/10.1155/2014/602526
Review Article

Emerging Biomarkers and Metabolomics for Assessing Toxic Nephropathy and Acute Kidney Injury (AKI) in Neonatology

1Department of Laboratory Medicine, IRCCS San Martino-IST, University Hospital, National Institute for Cancer Research, Largo Rosanna Benzi 10, 16132 Genoa, Italy
2Department of Pediatrics and Clinical Medicine, Section of Neonatal Intensive Care Unit, Puericulture Institute and Neonatal Section, Azienda Mista and University of Cagliari, 09042 Cagliari, Italy
3Division of Pediatric Clinical Pharmacology, Children’s National Medical Center, Washington, DC 20010, USA

Received 19 February 2014; Accepted 25 March 2014; Published 11 June 2014

Academic Editor: Pasquale Ditonno

Copyright © 2014 M. Mussap et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. C. de Jesus, A. Pappas, S. Shankaran et al., “Risk factors for post-neonatal intensive care unit discharge mortality among extremely low birth weight infants,” Journal of Pediatrics, vol. 161, no. 1, pp. 70.e2–74.e2, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Cerda, “Oliguria: an earlier and accurate biomarker of acute kidney injury,” Kidney International, vol. 80, no. 7, pp. 699–701, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. N. G. DeSanto, G. Capasso, P. Anastasio et al., “Renal functional reserve in children with and without renal disease,” Nephron, vol. 59, no. 1, pp. 1–6, 1991. View at Google Scholar · View at Scopus
  4. S. Hellerstein, M. Berenbom, P. Erwin, N. Wilson, and S. DiMaggio, “Measurement of renal functional reserve in children,” Pediatric Nephrology, vol. 19, no. 10, pp. 1132–1136, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Akcan-Arikan, M. Zappitelli, L. L. Loftis, K. K. Washburn, L. S. Jefferson, and S. L. Goldstein, “Modified RIFLE criteria in critically ill children with acute kidney injury,” Kidney International, vol. 71, no. 10, pp. 1028–1035, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. M. R. Sutherland, L. Gubhaju, and M. J. Black, “Stereological assessment of renal development in a baboon model of preterm birth,” Journal of the American Society of Nephrology, vol. 22, supplemnt 1, pp. 1365–1374, 2011. View at Publisher · View at Google Scholar
  7. M. J. Solhaug, P. M. Bolger, and P. A. Jose, “The developing kidney and environmental toxins,” Pediatrics, vol. 113, no. 4, pp. 1084–1091, 2004. View at Google Scholar · View at Scopus
  8. K. Sakurada, “Environmental epigenetic modifications and reprogramming-recalcitrant genes,” Stem Cell Research, vol. 4, no. 3, pp. 157–164, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Puddu, V. Fanos, F. Podda, and M. Zaffanello, “The kidney from prenatal to adult life: Perinatal programming and reduction of number of nephrons during development,” American Journal of Nephrology, vol. 30, no. 2, pp. 162–170, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. V. Fanos, M. Puddu, A. Reali, A. Atzei, and M. Zaffanello, “Perinatal nutrient restriction reduces nephron endowment increasing renal morbidity in adulthood: a review,” Early Human Development, vol. 86, no. 1, pp. S37–S42, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Faa, C. Gerosa, D. Fanni et al., “Marked interindividual variability in renal maturation of preterm infants: lessons from autopsy,” The Journal of Maternal-Fetal & Neonatal Medicine, vol. 23, no. 3, pp. 129–133, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Faa, C. Gerosa, D. Fanni et al., “Morphogenesis and molecular mechanisms involved in human kidney development,” Journal of Cellular Physiology, vol. 227, no. 3, pp. 1257–1268, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. W. L. Chiou and F. H. Hsu, “Pharmacokinetics of creatinine in man and its implications in the monitoring of renal function and in dosage regimen modifications in patients with renal insufficiency,” Journal of Clinical Pharmacology, vol. 15, no. 5-6, pp. 427–434, 1975. View at Google Scholar · View at Scopus
  14. S. M. Moran and B. D. Myers, “Course of acute renal failure studied by a model of creatinine kinetics,” Kidney International, vol. 27, no. 6, pp. 928–937, 1985. View at Google Scholar · View at Scopus
  15. K. Doi, P. S. T. Yuen, C. Eisner et al., “Reduced production of creatinine limits its use as marker of kidney injury in sepsis,” Journal of the American Society of Nephrology, vol. 20, no. 6, pp. 1217–1221, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. S. S. Waikar and J. V. Bonventre, “Creatinine kinetics and the definition of acute kidney injury,” Journal of the American Society of Nephrology, vol. 20, no. 3, pp. 672–679, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. S. G. Coca, A. J. Peixoto, A. X. Garg, H. M. Krumholz, and C. R. Parikh, “The prognostic importance of a small acute decrement in kidney function in hospitalized patients: a systematic review and meta-analysis,” American Journal of Kidney Diseases, vol. 50, no. 5, pp. 712–720, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. R. L. Mehta, “Biomarker explorations in acute kidney injury: the journey continues,” Kidney International, vol. 80, no. 4, pp. 332–334, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. J.-S. Rachoin, R. Daher, C. Moussallem et al., “The fallacy of the BUN: creatinine ratio in critically ill patients,” Nephrology Dialysis Transplantation, vol. 27, no. 6, pp. 2248–2254, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. J. C. Chambers, W. Zhang, G. M. Lord et al., “Genetic loci influencing kidney function and chronic kidney disease,” Nature Genetics, vol. 42, no. 5, pp. 373–375, 2010. View at Google Scholar
  21. K. Luttropp, B. Lindholm, J. J. Carrero et al., “Genetics/genomics in chronic kidney disease—towards personalized medicine?” Seminars in Dialysis, vol. 22, no. 4, pp. 417–422, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. F. P. Schena, G. Cerullo, D. D. Torres et al., “Searching for IgA nephropathy candidate genes: genetic studies combined with high throughput innovative investigations,” Contributions to Nephrology, vol. 157, pp. 80–89, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Nordfors, K. Luttropp, J. J. Carrero et al., “Genetic studies in chronic kidney disease: basic concepts,” Journal of Nephrology, vol. 25, no. 2, pp. 141–149, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Devarajan, J. Mishra, S. Supavekin, L. T. Patterson, and S. S. Potter, “Gene expression in early ischemic renal injury: clues towards pathogenesis, biomarker discovery, and novel therapeutics,” Molecular Genetics and Metabolism, vol. 80, no. 4, pp. 365–376, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Nistala, M. R. Hayden, V. G. Demarco et al., “Prenatal programming and epigenetics in the genesis of the cardiorenal syndrome,” CardioRenal Medicine, vol. 1, no. 4, pp. 243–254, 2011. View at Publisher · View at Google Scholar
  26. R. L. Jirtle and M. K. Skinner, “Environmental epigenomics and disease susceptibility,” Nature Reviews Genetics, vol. 8, no. 4, pp. 253–262, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. M. K. Skinner, “Environmental epigenomics and disease susceptibility,” The EMBO Reports, vol. 12, no. 7, pp. 620–622, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. A. D. Goldberg, C. D. Allis, and E. Bernstein, “Epigenetics: a landscape takes shape,” Cell, vol. 128, no. 4, pp. 635–638, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. A. P. Feinberg, “Epigenetics at the epicenter of modern medicine,” Journal of the American Medical Association, vol. 299, no. 11, pp. 1345–1350, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Pujadas and A. P. Feinberg, “Regulated noise in the epigenetic landscape of development and disease,” Cell, vol. 148, no. 6, pp. 1123–1131, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. A. P. Feinberg, “Epigenomics reveals a functional genome anatomy and a new approach to common disease,” Nature Biotechnology, vol. 28, no. 10, pp. 1049–1052, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Jenuwein and C. D. Allis, “Translating the histone code,” Science, vol. 293, no. 5532, pp. 1074–1080, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. A. P. Feinberg, “Phenotypic plasticity and the epigenetics of human disease,” Nature, vol. 447, no. 7143, pp. 433–440, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. V. Liakopoulos, P. I. Georgianos, T. Eleftheriadis, and P. A. Sarafidis, “Epigenetic mechanisms and kidney diseases,” Current Medicinal Chemistry, vol. 18, no. 12, pp. 1733–1739, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. R. S. Dwivedi, J. G. Herman, T. A. McCaffrey, and D. S. C. Raj, “Beyond genetics: epigenetic code in chronic kidney disease,” Kidney International, vol. 79, no. 1, pp. 23–32, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. X. B. Ling and K. G. Sylvester, “Proteomics and biomarkers in neonatology,” NeoReviews, vol. 12, no. 10, pp. e585–e591, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. G. L. Hortin and D. Sviridov, “Diagnostic potential for urinary proteomics,” Pharmacogenomics, vol. 8, no. 3, pp. 237–255, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. S. P. Gygi and R. Aebersold, “Mass spectrometry and proteomics,” Current Opinion in Chemical Biology, vol. 4, no. 5, pp. 489–494, 2000. View at Publisher · View at Google Scholar · View at Scopus
  39. E. F. Petricoin, A. M. Ardekani, B. A. Hitt et al., “Use of proteomic patterns in serum to identify ovarian cancer,” The Lancet, vol. 359, no. 9306, pp. 572–577, 2002. View at Google Scholar
  40. R. Richter, P. Schulz-Knappe, M. Schrader et al., “Composition of the peptide fraction in human blood plasma: database of circulating human peptides,” Journal of Chromatography B: Biomedical Sciences and Applications, vol. 726, no. 1-2, pp. 25–35, 1999. View at Publisher · View at Google Scholar · View at Scopus
  41. C. I. Balog, P. J. Hensbergen, R. Derks et al., “Novel automated biomarker discovery work flow for urinary peptidomics,” Clinical Chemistry, vol. 55, no. 1, pp. 117–125, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. A. G. W. Norden, P. Rodriguez-Cutillas, and R. J. Unwin, “Clinical urinary peptidomics: learning to walk before we can run,” Clinical Chemistry, vol. 53, no. 3, pp. 375–376, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. G. M. Fiedler, S. Baumann, A. Leichtle et al., “Standardized peptidome profiling of human urine by magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry,” Clinical Chemistry, vol. 53, no. 3, pp. 421–428, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Devarajan, “Emerging urinary biomarkers in the diagnosis of acute kidney injury,” Expert Opinion on Medical Diagnostics, vol. 2, no. 4, pp. 387–398, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. E. Y. Xu, W. H. Schaefer, and Q. Xu, “Metabolomics in pharmaceutical research and development: metabolites, mechanisms and pathways,” Current Opinion in Drug Discovery and Development, vol. 12, no. 1, pp. 40–52, 2009. View at Google Scholar · View at Scopus
  46. L. K. Schnackenberg, “Global metabolic profiling and its role in systems biology to advance personalized medicine in the 21st century,” Expert Review of Molecular Diagnostics, vol. 7, no. 3, pp. 247–259, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. J. K. Nicholson, J. C. Lindon, and E. Holmes, “‘Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data,” Xenobiotica, vol. 29, no. 11, pp. 1181–1189, 1999. View at Google Scholar · View at Scopus
  48. J. C. Lindon and J. K. Nicholson, “Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics,” Annual Review of Analytical Chemistry, vol. 1, no. 1, pp. 45–69, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. S. G. Oliver, M. K. Winson, D. B. Kell, and F. Baganz, “Systematic functional analysis of the yeast genome,” Trends in Biotechnology, vol. 16, no. 9, pp. 373–378, 1998. View at Publisher · View at Google Scholar · View at Scopus
  50. R. Goodacre, S. Vaidyanathan, W. B. Dunn, G. G. Harrigan, and D. B. Kell, “Metabolomics by numbers: acquiring and understanding global metabolite data,” Trends in Biotechnology, vol. 22, no. 5, pp. 245–252, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. U. Christians, J. Albuisson, J. Klawitter, and J. Klawitter, “The role of metabolomics in the study of kidney diseases and in the development of diagnostic tools,” in Biomarkers in Kidney Disease, C. L. Edelstein, Ed., pp. 39–100, Elsevier Academic Press, San Francisco, Calif, USA, 2011. View at Google Scholar
  52. M. Oldiges, S. Lütz, S. Pflug, K. Schroer, N. Stein, and C. Wiendahl, “Metabolomics: current state and evolving methodologies and tools,” Applied Microbiology and Biotechnology, vol. 76, no. 3, pp. 495–511, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. W. J. Griffiths and Y. Wang, “Mass spectrometry: from proteomics to metabolomics and lipidomics,” Chemical Society Reviews, vol. 38, no. 7, pp. 1882–1896, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. D. S. Wishart, D. Tzur, C. Knox et al., “HMDB: the human metabolome database,” Nucleic Acids Research, vol. 35, supplement 1, pp. D521–D526, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. D. S. Wishart, C. Knox, A. C. Guo et al., “HMDB: a knowledgebase for the human metabolome,” Nucleic Acids Research, vol. 37, supplement 1, no. 1, pp. D603–D610, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. N. V. Reo, “NMR-based metabolomics,” Drug and Chemical Toxicology, vol. 25, no. 4, pp. 375–382, 2002. View at Publisher · View at Google Scholar · View at Scopus
  57. J. M. Fonville, A. D. Maheir, M. Coen, E. Holmes, J. C. Lindon, and J. K. Nicholson, “Evaluation of full-resolution J-resolved1H NMR projections of biofluids for metabonomics information retrieval and biomarker identification,” Analytical Chemistry, vol. 82, no. 5, pp. 1811–1821, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Brown, D. C. Wedge, R. Goodacre et al., “Automated workflows for accurate mass-based putative metabolite identification in LC/MS-derived metabolomic datasets,” Bioinformatics, vol. 27, no. 8, pp. 1108–1112, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Brown, W. B. Dunn, P. Dobson et al., “Mass spectrometry tools and metabolite-specific databases for molecular identification in metabolomics,” Analyst, vol. 134, no. 7, pp. 1322–1332, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. O. Beckonert, H. C. Keun, T. M. D. Ebbels et al., “Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts,” Nature protocols, vol. 2, no. 11, pp. 2692–2703, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. S. H. G. Khoo and M. Al-Rubeai, “Metabolomics as a complementary tool in cell culture,” Biotechnology and Applied Biochemistry, vol. 47, no. 2, pp. 71–84, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. Z. Pan and D. Raftery, “Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics,” Analytical and Bioanalytical Chemistry, vol. 387, no. 2, pp. 525–527, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. K. K. Pasikanti, P. C. Ho, and E. C. Y. Chan, “Gas chromatography/mass spectrometry in metabolic profiling of biological fluids,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 871, no. 2, pp. 202–211, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. D. I. Ellis and R. Goodacre, “Metabolic fingerprinting in disease diagnosis: biomedical applications of infrared and Raman spectroscopy,” Analyst, vol. 131, no. 8, pp. 875–885, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. C. Krafft, G. Steiner, C. Beleites, and R. Salzer, “Disease recognition by infrared and Raman spectroscopy,” Journal of Biophotonics, vol. 2, no. 1-2, pp. 13–28, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. N. Rifai, M. A. Gillette, and S. A. Carr, “Protein biomarker discovery and validation: the long and uncertain path to clinical utility,” Nature Biotechnology, vol. 24, no. 8, pp. 971–983, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. H. G. Gika, G. A. Theodoridis, and I. D. Wilson, “Liquid chromatography and ultra-performance liquid chromatography-mass spectrometry fingerprinting of human urine. Sample stability under different handling and storage conditions for metabonomics studies,” Journal of Chromatography A, vol. 1189, no. 1-2, pp. 314–322, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. U. Christians, J. Klawitter, J. Klawitter, N. Brunner, and V. Schmitz, “Biomarkers of immunosuppressant organ toxicity after transplantation: status, concepts and misconceptions,” Expert Opinion on Drug Metabolism and Toxicology, vol. 7, no. 2, pp. 175–200, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. C. U. Niemann and N. J. Serkova, “Biochemical mechanisms of nephrotoxicity: application for metabolomics,” Expert Opinion on Drug Metabolism and Toxicology, vol. 3, no. 4, pp. 527–544, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. D. Wishart, “Metabolomics: a complementary tool in renal transplantation,” Contributions to Nephrology, vol. 160, pp. 76–87, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. J. Chen, H. Wen, J. Liu et al., “Metabonomics study of the acute graft rejection in rat renal transplantation using reversed-phase liquid chromatography and hydrophilic interaction chromatography coupled with mass spectrometry,” Molecular BioSystems, vol. 8, no. 3, pp. 871–878, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. R. Roberts, W. Rodriguez, D. Murphy, and T. Crescenzi, “Pediatric drug labeling: improving the safety and efficacy of pediatric therapies,” Journal of the American Medical Association, vol. 290, no. 7, pp. 905–911, 2003. View at Publisher · View at Google Scholar · View at Scopus
  73. V. Fanos, L. Barberini, R. Antonucci, and L. Atzori, “Metabolomics in neonatology and pediatrics,” Clinical Biochemistry, vol. 44, no. 7, pp. 452–454, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. V. Fanos, R. Antonucci, L. Barberini, and L. Atzori, “Chapter 7. Urinary metabolomics in newborns and Infants,” in Advances in Clinical Chemistry, vol. 58, pp. 193–223, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. V. Fanos, R. Antonucci, L. Barberini, A. Noto, and L. Atzori, “Clinical application of metabolomics in neonatology,” The Journal of Maternal-Fetal & Neonatal Medicine, vol. 25, no. 1, pp. 104–109, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. L. Atzori, R. Antonucci, L. Barberini et al., “1H NMR-based metabolomic analysis of urine from preterm and term neonates,” Frontiers in Bioscience, vol. 3, no. 3, pp. 1005–1012, 2011. View at Google Scholar · View at Scopus
  77. L. Atzori, J. L. Griffin, A. Noto, and V. Fanos, “Review metabolomics: a new approach to drug delivery in perinatology,” Current Medicinal Chemistry, vol. 19, no. 27, pp. 4654–4661, 2012. View at Google Scholar · View at Scopus
  78. V. Fanos, L. Barberini, R. Antonucci, and L. Atzori, “Pharma-metabolomics in neonatology: is it a dream or a fact?” Current Pharmaceutical Design, vol. 18, no. 21, pp. 2996–3006, 2012. View at Google Scholar · View at Scopus
  79. L. Atzori, R. Antonucci, L. Barberini et al., “1H NMR-based metabolic profiling of urine from children with nephrouropathies,” Frontiers in Bioscience, vol. 2, no. 2, pp. 725–732, 2010. View at Google Scholar · View at Scopus
  80. A. Dess, L. Atzori, A. Noto et al., “Metabolomics in newborns with intrauterine growth retardation (IUGR): urine reveals markers of metabolic syndrome,” The Journal of Maternal-Fetal & Neonatal Medicine, vol. 24, supplement 2, pp. 35–39, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. A. Fabiano, D. Gazzolo, L. J. I. Zimmermann et al., “Metabolomic analysis of bronchoalveolar lavage fluid in preterm infants complicated by respiratory distress syndrome: preliminary results,” The Journal of Maternal-Fetal & Neonatal Medicine, vol. 24, supplement 2, pp. 55–58, 2011. View at Google Scholar · View at Scopus
  82. A. Atzei, L. Atzori, C. Moretti et al., “Metabolomics in paediatric respiratory diseases and bronchiolitis,” The Journal of Maternal-Fetal & Neonatal Medicine, vol. 24, no. 2, pp. 59–62, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. L. Atzori, M. Mussap, A. Noto et al., “Clinical metabolomics and urinary NGAL for the early prediction of chronic kidney disease in healthy adults born ELBW,” The Journal of Maternal-Fetal & Neonatal Medicine, vol. 24, pp. 40–43, 2011. View at Google Scholar · View at Scopus
  84. R. H. Weiss and K. Kim, “Metabolomics in the study of kidney diseases,” Nature Reviews Nephrology, vol. 8, no. 1, pp. 22–33, 2012. View at Publisher · View at Google Scholar · View at Scopus
  85. R. D. Hawkins, G. C. Hon, and B. Ren, “Next-generation genomics: an integrative approach,” Nature Reviews Genetics, vol. 11, no. 7, pp. 476–486, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. F. M. Goodsaid, M. Blank, F. Dieterle et al., “Novel biomarkers of acute kidney toxicity,” Clinical Pharmacology and Therapeutics, vol. 86, no. 5, pp. 490–496, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. L. Kjeldsen, A. H. Johnsen, H. Sengelov, and N. Borregaard, “Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase,” The Journal of Biological Chemistry, vol. 268, no. 14, pp. 10425–10432, 1993. View at Google Scholar · View at Scopus
  88. T. H. Flo, K. D. Smith, S. Sato et al., “Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron,” Nature, vol. 432, no. 7019, pp. 917–921, 2004. View at Publisher · View at Google Scholar · View at Scopus
  89. J. Mishra, K. Mori, Q. Ma et al., “Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin,” Journal of the American Society of Nephrology, vol. 15, no. 12, pp. 3073–3082, 2004. View at Publisher · View at Google Scholar · View at Scopus
  90. K. Mori, H. T. Lee, D. Rapoport et al., “Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury,” The Journal of Clinical Investigation, vol. 115, no. 3, pp. 610–621, 2005. View at Publisher · View at Google Scholar · View at Scopus
  91. J. A. Gwira, F. Wei, S. Ishibe, J. M. Ueland, J. Barasch, and L. G. Cantley, “Expression of neutrophil gelatinase-associated lipocalin regulates epithelial morphogenesis in vitro,” The Journal of Biological Chemistry, vol. 280, no. 9, pp. 7875–7882, 2005. View at Publisher · View at Google Scholar · View at Scopus
  92. J. B. Cowland and N. Borregaard, “Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans,” Genomics, vol. 45, no. 1, pp. 17–23, 1997. View at Publisher · View at Google Scholar · View at Scopus
  93. L. Kjeldsen, D. F. Bainton, H. Sengeløv, and N. Borregaard, “Identification of neutrophil gelatinase-associated lipocalin as a novel matrix protein of specific granules in human neutrophils,” Blood, vol. 83, no. 3, pp. 799–807, 1994. View at Google Scholar · View at Scopus
  94. A. Friedl, S. P. Stoesz, P. Buckley, and M. N. Gould, “Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression,” Histochemical Journal, vol. 31, no. 7, pp. 433–441, 1999. View at Publisher · View at Google Scholar · View at Scopus
  95. P. Devarajan, “Neutrophil gelatinase-associated lipocalin: new paths for an old shuttle,” Cancer Therapy, vol. 5(B), pp. 463–470, 2007. View at Google Scholar
  96. P. Tewary, C. Redmond, M. Clifton et al., “Neutrophil gelatinase-associated lipocalin (NGAL): endogenous activators of the immune system,” The Journal of Immunology, vol. 184, p. 89, 2010. View at Google Scholar
  97. V. Hvidberg, C. Jacobsen, R. K. Strong, J. B. Cowland, S. K. Moestrup, and N. Borregaard, “The endocytic receptor megalin binds the iron transporting neutrophil-gelatinase-associated lipocalin with high affinity and mediates its cellular uptake,” FEBS Letters, vol. 579, no. 3, pp. 773–777, 2005. View at Publisher · View at Google Scholar · View at Scopus
  98. C. Langelueddecke, E. Roussa, R. A. Fenton, N. A. Wolff, W.-K. Lee, and F. Thévenod, “Lipocalin-2 (24p3/neutrophil gelatinase-associated lipocalin (NGAL)) receptor is expressed in distal nephron and mediates protein endocytosis,” The Journal of Biological Chemistry, vol. 287, no. 1, pp. 159–169, 2012. View at Publisher · View at Google Scholar · View at Scopus
  99. N. Paragas, A. Qiu, Q. Zhang et al., “The Ngal reporter mouse detects the response of the kidney to injury in real time,” Nature Medicine, vol. 17, no. 2, pp. 216–222, 2011. View at Publisher · View at Google Scholar · View at Scopus
  100. A. Viau, K. El Karoui, D. Laouari et al., “Lipocalin 2 is essential for chronic kidney disease progression in mice and humans,” Journal of Clinical Investigation, vol. 120, no. 11, pp. 4065–4076, 2010. View at Publisher · View at Google Scholar · View at Scopus
  101. K. M. Schmidt-Ott, K. Mori, A. Kalandadze et al., “Neutrophil gelatinase-associated lipocalin-mediated iron traffic in kidney epithelia,” Current Opinion in Nephrology and Hypertension, vol. 15, no. 4, pp. 442–449, 2006. View at Publisher · View at Google Scholar · View at Scopus
  102. K. M. Schmidt-Ott, K. Mori, Y. L. Jau et al., “Dual action of neutrophil gelatinase-associated lipocalin,” Journal of the American Society of Nephrology, vol. 18, no. 2, pp. 407–413, 2007. View at Publisher · View at Google Scholar · View at Scopus
  103. F. C. Grenier, S. Ali, H. Syed et al., “Evaluation of the ARCHITECT urine NGAL assay: assay performance, specimen handling requirements and biological variability,” Clinical Biochemistry, vol. 43, no. 6, pp. 615–620, 2010. View at Publisher · View at Google Scholar · View at Scopus
  104. L. Yan, N. Borregaard, L. Kjeldsen, and M. A. Moses, “The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL): modulation of MMP-9 activity by NGAL,” The Journal of Biological Chemistry, vol. 276, no. 40, pp. 37258–37265, 2001. View at Publisher · View at Google Scholar · View at Scopus
  105. L. Cai, J. Rubin, W. Han, P. Venge, and S. Xu, “The origin of multiple molecular forms in urine of HNL/NGAL,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 12, pp. 2229–2235, 2010. View at Publisher · View at Google Scholar · View at Scopus
  106. S. Hatipoglu, E. Sevketoglu, A. Gedikbasi et al., “Urinary MMP-9/NGAL complex in children with acute cystitis,” Pediatric Nephrology, vol. 26, no. 8, pp. 1263–1268, 2011. View at Publisher · View at Google Scholar · View at Scopus
  107. T. L. Nickolas, C. S. Forster, M. E. Sise et al., “NGAL (Lcn2) monomer is associated with tubulointerstitial damage in chronic kidney disease,” Kidney International, vol. 82, no. 6, pp. 718–722, 2012. View at Publisher · View at Google Scholar · View at Scopus
  108. M. Mussap, A. Noto, M. Fravega, and V. Fanos, “Urine neutrophil gelatinase-associated lipocalin (uNGAL) and netrin-1: are they effectively improving the clinical management of sepsis-induced acute kidney injury (AKI)?” The Journal of Maternal-Fetal & Neonatal Medicine, vol. 24, supplement 2, pp. 15–17, 2011. View at Google Scholar · View at Scopus
  109. J. Mishra, M. A. Qing, A. Prada et al., “Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury,” Journal of the American Society of Nephrology, vol. 14, no. 10, pp. 2534–2543, 2003. View at Publisher · View at Google Scholar · View at Scopus
  110. J. Mishra, K. Mori, Q. Ma, C. Kelly, J. Barasch, and P. Devarajan, “Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity,” American Journal of Nephrology, vol. 24, no. 3, pp. 307–315, 2004. View at Publisher · View at Google Scholar · View at Scopus
  111. M. Haase, R. Bellomo, P. Devarajan, P. Schlattmann, and A. Haase-Fielitz, “Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis,” American Journal of Kidney Diseases, vol. 54, no. 6, pp. 1012–1024, 2009. View at Publisher · View at Google Scholar · View at Scopus
  112. M. Haase, P. Devarajan, A. Haase-Fielitz et al., “The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies,” Journal of the American College of Cardiology, vol. 57, no. 17, pp. 1752–1761, 2011. View at Publisher · View at Google Scholar · View at Scopus
  113. J. Mishra, C. Dent, R. Tarabishi et al., “Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery,” The Lancet, vol. 365, no. 9466, pp. 1231–1238, 2005. View at Publisher · View at Google Scholar · View at Scopus
  114. F. I. Fadel, A. M. O. Abdel Rahman, M. F. Mohamed et al., “Plasma neutrophil gelatinase-associated lipocalin as an early biomarker for prediction of acute kidney injury after cardio-pulmonary bypass in pediatric cardiac surgery,” Archives of Medical Science, vol. 8, no. 2, pp. 250–255, 2012. View at Publisher · View at Google Scholar · View at Scopus
  115. F. Ampatzidou, C.-P. Koutsogiannidis, O. Ananiadou, M. Liosi, T. Asteri, and G. Drossos, “Neutrophil gelatinase-associated lipocalin as emerging biomarker of acute renal failure in renal transplant patient after coronary artery bypass surgery,” Journal of Cardiovascular Surgery, vol. 53, no. 6, pp. 805–808, 2012. View at Google Scholar · View at Scopus
  116. E. Bignami, E. Frati, F. Ceriotti et al., “Urinary neutrophil gelatinase-associated lipocalin as an early predictor of prolonged intensive care unit stay after cardiac surgery,” Annals of Cardiac Anaesthesia, vol. 15, no. 1, pp. 13–17, 2012. View at Publisher · View at Google Scholar · View at Scopus
  117. F. Capuano, M. Goracci, R. Luciani et al., “Neutrophil gelatinase-associated lipocalin levels after use of mini-cardiopulmonary bypass system,” Interactive Cardiovascular and Thoracic Surgery, vol. 9, no. 5, pp. 797–801, 2009. View at Publisher · View at Google Scholar · View at Scopus
  118. J. Ho, M. Lucy, O. Krokhin et al., “Mass spectrometry-based proteomic analysis of urine in acute kidney injury following cardiopulmonary bypass: a nested case-control study,” American Journal of Kidney Diseases, vol. 53, no. 4, pp. 584–595, 2009. View at Publisher · View at Google Scholar · View at Scopus
  119. G. Wagener, G. Gubitosa, S. Wang, N. Borregaard, M. Kim, and H. T. Lee, “Urinary neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery,” American Journal of Kidney Diseases, vol. 52, no. 3, pp. 425–433, 2008. View at Publisher · View at Google Scholar · View at Scopus
  120. M. Bennett, C. L. Dent, Q. Ma et al., “Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 3, pp. 665–673, 2008. View at Publisher · View at Google Scholar · View at Scopus
  121. I. E. Hall, S. G. Yarlagadda, S. G. Coca et al., “IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation,” Journal of the American Society of Nephrology, vol. 21, no. 1, pp. 189–197, 2010. View at Publisher · View at Google Scholar · View at Scopus
  122. C. R. Parikh, A. Jani, J. Mishra et al., “Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation,” American Journal of Transplantation, vol. 6, no. 7, pp. 1639–1645, 2006. View at Publisher · View at Google Scholar · View at Scopus
  123. H. Trachtman, E. Christen, A. Cnaan et al., “Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury,” Pediatric Nephrology, vol. 21, no. 7, pp. 989–994, 2006. View at Publisher · View at Google Scholar · View at Scopus
  124. R. Hirsch, C. Dent, H. Pfriem et al., “NGAL is an early predictive biomarker of contrast-induced nephropathy in children,” Pediatric Nephrology, vol. 22, no. 12, pp. 2089–2095, 2007. View at Publisher · View at Google Scholar · View at Scopus
  125. D. S. Wheeler, P. Devarajan, Q. Ma et al., “Serum neutrophil gelatinase-associated lipocalin (NGAL) as a marker of acute kidney injury in critically ill children with septic shock,” Critical Care Medicine, vol. 36, no. 4, pp. 1297–1303, 2008. View at Publisher · View at Google Scholar · View at Scopus
  126. A. P. Lavery, J. K. Meinzen-Derr, E. Anderson et al., “Urinary NGAL in premature infants,” Pediatric Research, vol. 64, no. 4, pp. 423–428, 2008. View at Publisher · View at Google Scholar · View at Scopus
  127. T. K. Huynh, D. A. Bateman, E. Parravicini et al., “Reference values of urinary neutrophil gelatinase-associated lipocalin in very low birth weight infants,” Pediatric Research, vol. 66, no. 5, pp. 528–532, 2009. View at Publisher · View at Google Scholar · View at Scopus
  128. E. Parravicini, S. L. Nemerofsky, K. A. Michelson et al., “Urinary neutrophil gelatinase-associated lipocalin is a promising biomarker for late onset culture-positive sepsis in very low birth weight infants,” Pediatric Research, vol. 67, no. 6, pp. 636–640, 2010. View at Publisher · View at Google Scholar · View at Scopus
  129. M. Mussap, R. Degrandi, M. Fravega, and V. Fanos, “Acute kidney injury in critically ill infants: the role of urine neutrophil gelatinase-associated lipocalin (NGAL),” The Journal of Maternal-Fetal & Neonatal Medicine, vol. 23, no. 3, pp. 70–72, 2010. View at Publisher · View at Google Scholar · View at Scopus
  130. T. Ichimura, J. V. Bonventre, V. Bailly et al., “Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury,” The Journal of Biological Chemistry, vol. 273, no. 7, pp. 4135–4142, 1998. View at Publisher · View at Google Scholar · View at Scopus
  131. V. Bailly, Z. Zhang, W. Meier, R. Cate, M. Sanicola, and J. V. Bonventre, “Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration,” The Journal of Biological Chemistry, vol. 277, no. 42, pp. 39739–39748, 2002. View at Publisher · View at Google Scholar · View at Scopus
  132. V. K. Kuchroo, D. T. Umetsu, R. H. DeKruyff, and G. J. Freeman, “The TIM gene family: emerging roles in immunity and disease,” Nature Reviews Immunology, vol. 3, no. 6, pp. 454–462, 2003. View at Publisher · View at Google Scholar · View at Scopus
  133. G. Kaplan, A. Totsuka, P. Thompson, T. Akatsuka, Y. Moritsugu, and S. M. Feinstone, “Identification of a surface glycoprotein on African green monkey kidney cells as a receptor for hepatitis A virus,” The EMBO Journal, vol. 15, no. 16, pp. 4282–4296, 1996. View at Google Scholar · View at Scopus
  134. R. P. Amin, A. E. Vickers, F. Sistare et al., “Identification of putative gene-based markers of renal toxicity,” Environmental Health Perspectives, vol. 112, no. 4, pp. 465–479, 2004. View at Google Scholar · View at Scopus
  135. T. Ichimura, E. J. P. V. Asseldonk, B. D. Humphreys, L. Gunaratnam, J. S. Duffield, and J. V. Bonventre, “Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells,” The Journal of Clinical Investigation, vol. 118, no. 5, pp. 1657–1668, 2008. View at Publisher · View at Google Scholar · View at Scopus
  136. J. Savill and V. Fadok, “Corpse clearance defines the meaning of cell death,” Nature, vol. 407, no. 6805, pp. 784–788, 2000. View at Publisher · View at Google Scholar · View at Scopus
  137. F. Waanders, M. M. Van Timmeren, C. A. Stegeman, S. J. L. Bakker, and H. Van Goor, “Kidney injury molecule-1 in renal disease,” Journal of Pathology, vol. 220, no. 1, pp. 7–16, 2010. View at Publisher · View at Google Scholar · View at Scopus
  138. T. Ichimura, C. C. Hung, S. A. Yang, J. L. Stevens, and J. V. Bonventre, “Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury,” The American Journal of Physiology: Renal Physiology, vol. 286, no. 3, pp. F552–F563, 2004. View at Google Scholar · View at Scopus
  139. V. S. Vaidya, S. S. Waikar, M. A. Ferguson et al., “Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans,” Clinical and Translational Science, vol. 1, no. 3, pp. 200–208, 2008. View at Publisher · View at Google Scholar · View at Scopus
  140. W. K. Han, V. Bailly, R. Abichandani, R. Thadhani, and J. V. Bonventre, “Kidney Injury Molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury,” Kidney International, vol. 62, no. 1, pp. 237–244, 2002. View at Publisher · View at Google Scholar · View at Scopus
  141. Y. Zhou, V. S. Vaidya, R. P. Brown et al., “Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium,” Toxicological Sciences, vol. 101, no. 1, pp. 159–170, 2008. View at Publisher · View at Google Scholar · View at Scopus
  142. J. V. Bonventre, “Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure,” Journal of the American Society of Nephrology, vol. 14, no. 1, pp. S55–S61, 2003. View at Google Scholar · View at Scopus
  143. K. M. Park, J.-Y. Byun, C. Kramers, J. I. Kim, P. L. Huang, and J. V. Bonventre, “Inducible nitric-oxide synthase is an important contributor to prolonged protective effects of ischemic preconditioning in the mouse kidney,” The Journal of Biological Chemistry, vol. 278, no. 29, pp. 27256–27266, 2003. View at Publisher · View at Google Scholar · View at Scopus
  144. J. Pérez-Rojas, J. A. Blanco, C. Cruz et al., “Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity,” The American Journal of Physiology: Renal Physiology, vol. 292, no. 1, pp. F131–F139, 2007. View at Publisher · View at Google Scholar · View at Scopus
  145. W. C. Prozialeck, V. S. Vaidya, J. Liu et al., “Kidney injury molecule-1 is an early biomarker of cadmium nephrotoxicity,” Kidney International, vol. 72, no. 8, pp. 985–993, 2007. View at Publisher · View at Google Scholar · View at Scopus
  146. V. Fanos, R. Antonucci, M. Zaffanello, and M. Mussap, “Neonatal drug induced nephrotoxicity: old and next generation biomarkers for early detection and management of neonatal drug-induced nephrotoxicity, with special emphasis on uNGAL and on metabolomics,” Current Medicinal Chemistry, vol. 19, no. 27, pp. 4595–4605, 2012. View at Google Scholar
  147. W. K. Han, A. Alinani, C.-L. Wu et al., “Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma,” Journal of the American Society of Nephrology, vol. 16, no. 4, pp. 1126–1134, 2005. View at Publisher · View at Google Scholar · View at Scopus
  148. F. Lin, P. L. Zhang, X. J. Yang et al., “Human kidney injury molecule-1 (hKIM-1): a useful immunohistochemical marker for diagnosing renal cell carcinoma and ovarian clear cell carcinoma,” The American Journal of Surgical Pathology, vol. 31, no. 3, pp. 371–381, 2007. View at Publisher · View at Google Scholar · View at Scopus
  149. M. M. Van Timmeren, S. J. L. Bakker, V. S. Vaidya et al., “Tubular kidney injury molecule-1 in protein-overload nephropathy,” The American Journal of Physiology: Renal Physiology, vol. 291, no. 2, pp. F456–F464, 2006. View at Publisher · View at Google Scholar · View at Scopus
  150. E. W. Kuehn, K. M. Park, S. Somlo, and J. V. Bonventre, “Kidney injury molecule-1 expression in murine polycystic kidney disease,” The American Journal of Physiology: Renal Physiology, vol. 283, no. 6, pp. F1326–F1336, 2002. View at Google Scholar · View at Scopus
  151. J. J. McIntire, S. E. Umetsu, O. Akbari et al., “Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family,” Nature Immunology, vol. 2, no. 12, pp. 1109–1116, 2001. View at Publisher · View at Google Scholar · View at Scopus
  152. Z. Zhang, B. D. Humphreys, and J. V. Bonventre, “Shedding of the urinary biomarker kidney injury molecule-1 (KIM-1) is regulated by MAP kinases and juxtamembrane region,” Journal of the American Society of Nephrology, vol. 18, no. 10, pp. 2704–2714, 2007. View at Publisher · View at Google Scholar · View at Scopus
  153. P. L. Zhang, L. I. Rothblum, W. K. Han, T. M. Blasick, S. Potdar, and J. V. Bonventre, “Kidney injury molecule-1 expression in transplant biopsies is a sensitive measure of cell injury,” Kidney International, vol. 73, no. 5, pp. 608–614, 2008. View at Publisher · View at Google Scholar · View at Scopus
  154. M. M. Van Timmeren, V. S. Vaidya, R. M. Van Ree et al., “High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients,” Transplantation, vol. 84, no. 12, pp. 1625–1630, 2007. View at Publisher · View at Google Scholar · View at Scopus
  155. P. Perco and R. Oberbauer, “Kidney injury molecule-1 as a biomarker of acute kidney injury in renal transplant recipients,” Nature Clinical Practice Nephrology, vol. 4, no. 7, pp. 362–363, 2008. View at Publisher · View at Google Scholar · View at Scopus
  156. J. V. Bonventre, “Kidney injury molecule-1 (KIM-1): a urinary biomarker and much more,” Nephrology, Dialysis, Transplantation, vol. 24, no. 11, pp. 3265–3268, 2009. View at Publisher · View at Google Scholar · View at Scopus
  157. W. Huo, K. Zhang, Z. Nie, Q. Li, and F. Jin, “Kidney injury molecule-1 (KIM-1): a novel kidney-specific injury molecule playing potential double-edged functions in kidney injury,” Transplantation Reviews, vol. 24, no. 3, pp. 143–146, 2010. View at Publisher · View at Google Scholar · View at Scopus
  158. J. V. Bonventre, V. S. Vaidya, R. Schmouder, P. Feig, and F. Dieterle, “Next-generation biomarkers for detecting kidney toxicity,” Nature Biotechnology, vol. 28, no. 5, pp. 436–440, 2010. View at Publisher · View at Google Scholar · View at Scopus
  159. F. Dieterle, F. Sistare, F. Goodsaid et al., “Renal biomarker qualification submission: a dialog between the FDA-EMEA and predictive safety testing consortium,” Nature Biotechnology, vol. 28, no. 5, pp. 455–462, 2010. View at Publisher · View at Google Scholar · View at Scopus
  160. F. Waanders, V. S. Vaidya, H. van Goor et al., “Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial,” American Journal of Kidney Diseases, vol. 53, no. 1, pp. 16–25, 2009. View at Publisher · View at Google Scholar · View at Scopus
  161. V. S. Vaidya, V. Ramirez, T. Ichimura, N. A. Bobadilla, and J. V. Bonventre, “Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury,” The American Journal of Physiology: Renal Physiology, vol. 290, no. 2, pp. F517–F529, 2006. View at Publisher · View at Google Scholar · View at Scopus
  162. O. Liangos, M. C. Perianayagam, V. S. Vaidya et al., “Urinary N-acetyl-β-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure,” Journal of the American Society of Nephrology, vol. 18, no. 3, pp. 904–912, 2007. View at Publisher · View at Google Scholar · View at Scopus
  163. A. Wasilewska, K. Taranta-Janusz, W. Dȩbek, W. Zoch-Zwierz, and E. Kuroczycka-Saniutycz, “KIM-1 and NGAL: new markers of obstructive nephropathy,” Pediatric Nephrology, vol. 26, no. 4, pp. 579–586, 2011. View at Publisher · View at Google Scholar · View at Scopus
  164. D. J. Askenazi, R. Koralkar, E. B. Levitan et al., “Baseline values of candidate urine acute kidney injury biomarkers vary by gestational age in premature infants,” Pediatric Research, vol. 70, no. 3, pp. 302–306, 2011. View at Publisher · View at Google Scholar · View at Scopus
  165. K. Sean Eardley and P. Cockwell, “Macrophages and progressive tubulointerstitial disease,” Kidney International, vol. 68, no. 2, pp. 437–455, 2005. View at Publisher · View at Google Scholar · View at Scopus
  166. R. Munshi, A. Johnson, E. D. Siew et al., “MCP-1 gene activation marks acute kidney injury,” Journal of the American Society of Nephrology, vol. 22, no. 1, pp. 165–175, 2011. View at Publisher · View at Google Scholar · View at Scopus
  167. G. Grandaliano, L. Gesualdo, E. Ranieri et al., “Monocyte chemotactic peptide-1 expression in acute and chronic human nephritides: a pathogenetic role in interstitial monocytes recruitment,” Journal of the American Society of Nephrology, vol. 7, no. 6, pp. 906–913, 1996. View at Google Scholar · View at Scopus
  168. L. Gesualdo, S. Di Paolo, A. Calabró et al., “Expression of epidermal growth factor and its receptor in normal and diseased human kidney: an immunohistochemical and in situ hybridization study,” Kidney International, vol. 49, no. 3, pp. 656–665, 1996. View at Google Scholar · View at Scopus
  169. H. D. Humes, D. A. Cieslinski, T. M. Coimbra, J. M. Messana, and C. Galvao, “Epidermal growth factor enhances renal tubule cell regeneration and repair and accelerates the recovery of renal function in postischemic acute renal failure,” The Journal of Clinical Investigation, vol. 84, no. 6, pp. 1757–1761, 1989. View at Google Scholar · View at Scopus
  170. R. L. Chevalier, S. Goyal, J. T. Wolstenholme, and B. A. Thornhill, “Obstructive nephropathy in the neonatal rat is attenuated by epidermal growth factor,” Kidney International, vol. 54, no. 1, pp. 38–47, 1998. View at Publisher · View at Google Scholar · View at Scopus
  171. M. Plebani, V. Fanos, M. Mussap, M. De Paoli, B. J. Khoory, and E. M. Padovani, “Urinary excretion of human epidermal growth factor in premature infants requiring assisted ventilation over the first week of life,” Nephron, vol. 76, no. 2, pp. 225–226, 1997. View at Google Scholar · View at Scopus
  172. V. Fanos, C. Pizzini, M. Mussap, D. Benini, and M. Plebani, “Urinary epidermal growth factor in different renal conditions in children,” Renal Failure, vol. 23, no. 3-4, pp. 605–610, 2001. View at Publisher · View at Google Scholar · View at Scopus
  173. F. Bartoli, L. Gesualdo, G. Paradies et al., “Renal expression of monocyte chemotactic protein-1 and epidermal growth factor in children with obstructive hydronephrosis,” Journal of Pediatric Surgery, vol. 35, no. 4, pp. 569–572, 2000. View at Google Scholar · View at Scopus
  174. D. D. Torres, M. Rossini, C. Manno et al., “The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy,” Kidney International, vol. 73, no. 3, pp. 327–333, 2008. View at Publisher · View at Google Scholar · View at Scopus
  175. F. Bartoli, R. Penza, G. Aceto et al., “Urinary epidermal growth factor, monocyte chemotactic protein-1, and β2-microglobulin in children with ureteropelvic junction obstruction,” Journal of Pediatric Surgery, vol. 46, no. 3, pp. 530–536, 2011. View at Publisher · View at Google Scholar · View at Scopus
  176. E. C. Eichenwald and A. R. Stark, “Management and outcomes of very low birth weight,” The New England Journal of Medicine, vol. 358, no. 16, pp. 1700–1711, 2008. View at Publisher · View at Google Scholar · View at Scopus
  177. R. Koralkar, N. Ambalavanan, E. B. Levitan, G. McGwin, S. Goldstein, and D. Askenazi, “Acute kidney injury reduces survival in very low birth weight infants,” Pediatric Research, vol. 69, no. 4, pp. 354–358, 2011. View at Publisher · View at Google Scholar · View at Scopus